NCT00874887View on ClinicalTrials.gov

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2009

Conditions
Anti-biotic Resistance
Interventions
DRUG

moxifloxacin 0.5% HCI ophthalmic solution

1 drop in study eye three times a day for 14 days

DRUG

gatifloxacin ophthalmic solution 0.3%

1 drop in study eye four times a day for 14 days

Trial Locations (2)

Unknown

Minneapolis

Saskatoon

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT00874887 - A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms | Biotech Hunter | Biotech Hunter